Contact Us
Contact Us
Contact Us

Products and
Solutions

clinical development portfolioTranslating Innovation to Clinical Impact

InfiNano’s product portfolio encompasses both commercially available formulations addressing near-term clinical needs and advanced nanoplatform therapeutics in preclinical/clinical development stages, representing a balanced risk-return profile with multiple value inflection points. 

We have about FDA Approved 350+ Formulations at GMP manufacturing Plant at Pune. Most of our products are built on our innovative Nano Tech platform for deeper targeted absorption and extended bio-availability.  

  • Skin Care  
  • Derma  
  • Hair Care 
  • Wound Care 
  • Post Treatment Care (Chemo, Radiation, Botox, Surgery, Skin therapy) 
  • Veterinary (small & large animals)

Click here for faster Product conceptualization to Launch

BioMuCare™ – Nano-Enabled Oral Mucositis Management
  • Regulatory Status: Launching Q2 2025 | Nutraceutical / Medical Device Category..
  • Clinical Problem Statement: Chemotherapy and radiation-induced oral mucositis (OM) affects 40-80% of cancer patients receiving cytotoxic therapy, with severe grades (WHO Grade 3-4) occurring in 20-40%. OM causes significant morbidity, treatment interruptions, increased infection risk, and healthcare costs. Current management remains largely supportive with limited therapeutic options.
  • Technology Platform: Nano-encapsulated herbal bioactive delivery system utilizing phospholipid-based nanocarriers (80-200 nm) for enhanced mucosal penetration and sustained release. Formulation optimized for local tissue retention and gradual active ingredient release over 4-6 hours.
  • Formulation Characteristics:
    • Sugar-free, alcohol-free composition (diabetic-safe).
    • Nano-encapsulation enabling 3-5x enhanced bioavailability.
    • Non-irritant, pH-balanced for compromised mucosa.
    • Synergistic phytochemical composition with anti-inflammatory, antimicrobial, and healing-promoting activities.
  • Clinical Benefits:
    • Accelerated mucosal healing (40-60% reduction in healing time in preclinical models).
    • Significant pain reduction enabling improved nutritional intake.
    • Reduced infection rates and treatment interruptions.
    • Enhanced patient quality of life during cancer therapy.
  • Target Market Segments:
    • Hospital-based oncology departments.
    • Radiation therapy centers.
    • Outpatient cancer care facilities.
    • Technology licensing to oncology pharmaceutical companies.
  • Market Dynamics: Global OM treatment market: $1.85B (2024) → $3.72B (2034), 7.2% CAGR, driven by increasing cancer incidence and expanding indications for myeloablative chemotherapy.
CellWell R™ (CBI Gel) – Radiation Dermatitis Therapeutic
  • Regulatory Status: Launching Q2 2025 | GMP-Compliant Manufacturing.
  • Clinical Problem Statement: Radiation dermatitis (RD) occurs in approximately 95% of patients undergoing radiotherapy, with acute RD (Grade 2-3) in 20-35% causing significant morbidity, treatment delays, and decreased quality of life. Current standard-of-care remains largely symptomatic with limited disease-modifying options.
  • Technology Platform: Non-steroidal, nano-structured hydrogel incorporating plant-derived bioactives in nanoparticulate form (50-150 nm) for enhanced dermal penetration beyond stratum corneum. Sustained-release matrix enables prolonged therapeutic contact with affected tissue.
  • Formulation Characteristics:
    • Nano-enabled deep dermal penetration (verified via Franz diffusion cell studies).
    • Sustained-release kinetics providing 6-8 hour therapeutic duration.
    • Non-steroidal composition avoiding glucocorticoid-associated complications.
    • Hydrogel matrix providing optimal moisture balance for wound healing Integrated cooling effect reducing acute inflammatory response.
  • Pharmacological Actions:
    • Active epithelial regeneration promotion.
    • Anti-inflammatory activity reducing acute radiation response.
    • Analgesic properties for symptomatic relief.
    • Antioxidant activity mitigating radiation-induced oxidative damage.
  • Clinical Endpoints:
    • Reduction in RD severity (grade reduction).
    • Accelerated healing of established RD.
    • Decreased need for treatment interruptions.
    • Improved patient-reported outcomes.
  • Target Market Segments:
    • Radiation oncology departments.
    • Cancer treatment centers.
    • Patient support organizations.
    • International markets (GMP-ready for global registration).
  • Market Dynamics: Global RD management market: $470M (2024) → $700M (2034), 5% CAGR, with increasing demand for non-steroidal, evidence-based interventions.

additional commercial categoriesDiversified Portfolio Across Therapeutic Applications

Explore More
Oral Healthcare Portfolio
Nano-engineered formulations for dental and periodontal applications leveraging enhanced tissue penetration and sustained release characteristics.
Dermatology & Cosmeceuticals
Advanced delivery systems for therapeutic dermatology and evidence-based cosmeceutical applications with clinically measurable endpoints.
Advanced Wound Care
Nano-enabled formulations addressing complex wound environments including diabetic ulcers, pressure injuries, and surgical wounds requiring advanced healing modulation.
Veterinary Applications
Specialized nano-formulations adapted for companion animal and livestock healthcare applications.
Current Commercial Footprint
  • White-label manufacturing partnerships across 5 countries.
  • Established relationships with pharmaceutical distributors in India, GCC, and European markets.
  • Revenue-generating operations: ₹6 Cr annualized run-rate.
  • EBITDA-positive business model demonstrating operational efficiency.

Collaborating to Build a Smarter Future

Initiate Discussion